drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting CD7, enabling recognition and cytotoxic elimination of CD7-expressing malignant hematologic cells (e.g., T-ALL, CD7+ AML); on-target T-cell aplasia may occur.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti‑CD7 chimeric antigen receptor bind CD7 on malignant hematologic cells, triggering CAR signaling (CD3ζ with co‑stimulation) to activate, proliferate, release cytokines, and mediate cytotoxic killing; on‑target T‑cell aplasia can occur due to CD7 expression on normal T cells.
drug_name
CD7 CAR-T cells
nct_id_drug_ref
NCT05827835